Effect of Nebulized Magnesium Sulphate in Terms of the In-HospitalOutcome of Patients Admitted with Acute Exacerbation of ChronicObstructive Pulmonary disease
Abstract
To evaluate the efficacy of Magnesium Sulphate (MgSO4) with the conventional treatment in acute exacerbation chronic obstructive pulmonary disease (AECOPD)
This Quasi-experimental study was conducted in Department of Internal Medicine from July 2020 to July 2022. The study involved 160 patients in total. There were two groups of patients. Group A was nebulized with 250mg of MgSO4 four times a day along with conventional treatment. Group B was given only conventional treatment. Conventional treatment included oxygen inhalation, anti-cholinergic and beta-2 agonist nebulization, intravenous steroids, and intravenous antibiotics. Both groups were followed for five days to assess the effect of nebulized magnesium.
Group A required assisted ventilation for 2–3 days for 28% of the subjects (22 patients out of 80), while group B required it for 81% of the subjects (65 patients out of 80). In addition, only 9% of patients in group A and 8% of patients in group B needed assisted ventilation for four to five days. In comparison to group A, which had 33% of patients discharged on the fourth day and 20% on the fifth day or later, group B saw 53% of patients discharged on the fourth day and 20% on the fifth day or later. The results showed that PCO2 and peak expiratory flow rate (PEFR) have a significant variance between group A and group B and values have no significant variance between group A and group B on the first day and the last day.
Nebulized supplementation improves in-hospital outcomes in patients presenting with acute exacerbation of COPD as compared to the patients not receiving nebulized magnesium sulphate.
How to Cite This Article
Ain Q, Randhawa FA, Butt NF, Aslam A, Latif H, Rathore R. Effect of Nebulized Magnesium Sulphate in Terms of the In-HospitalOutcome of Patients Admitted with Acute Exacerbation of ChronicObstructive Pulmonary disease. J Pak Soc Intern Med. 2024;5(1):383–387. doi:10.70302/jpsim.v5i1.2406
Conflict of Interest
All authors declare no competing interests.
Funding
No specific funding was received for this research.
Funder information follows the Crossref Funder Registry standard.
References
- Rehman AU, Muhammad SA, Tasleem Z, Alsaedi A, Dar M, Iqbal MO, et al. Humanistic and socioeconomic burden of COPD patients and their caregivers in Malaysia. Scientific Rep. 2021;11(1):22598.
- Khan MA, Khan N, Walley JD, Khan MA, Hicks J, Ahmed M, et al. Effectiveness of delivering integrated COPD care at public healthcare facilities: a cluster randomised trial in Pakistan. BJGP Open. 2019;3(1):101634.
- Venkatesan P. GOLD COPD report: 2023 update. Lancet Resp Med. 2023 ;11(1):18.
- Hogea SP, Tudorache E, Fildan AP, Fira‐Mladinescu O, Marc M, Oancea C. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J. 2020;14(3):183-97.
- Erhabor GE, Adeniyi B, Arawomo AO, Akinwalere O, Adetona G, Fagbohun FT, et al. Acute Exacerbation of COPD: Clinical Perspectives and Literature Review. West Afr J Med. 2021;38(11):1129-42.
- Moghoofei M, Azimzadeh Jamalkandi S, Moein M, Salimian J, Ahmadi A. Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Infection. 2020;48(1):19-35. .
- Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med. 2020;41(3):421-38.
- Cazzola M, Calzetta L, Rogliani P, Matera MG. Triple therapy versus dual bronchodilation and inhaled corticosteroids/long-acting β-agonists in COPD: accumulating evidence from network meta-analyses. Pulm Ther. 2019;5(2):117-26..
- Zheng JP, Zhang J, Ma LJ, Chen P, Huang M, Ou XM, et al. Clinical outcomes of using nebulized budesonide as the initial treatment for acute exacerbations of chronic obstructive pulmonary disease: A post-hoc analysis. Int J Chron Obstruct Pulm Dis. 2019;14(9):2725-31.
- Jahanian F, Khatir IG, Ahidashti HA, Amirifard S. The Effect of Intravenous Magnesium Sulphate as an Adjuvant in the Treatment of Acute Exacerbations of COPD in the Emergency Department: A Double-Blind Randomized Clinical Trial. Ethiopian J Health Sci. 2021;31(2):267-74.
- Jahangir A, Zia Z, Niazi MR, Sahra S, Jahangir A, Sharif MA, et al. Efficacy of magnesium sulfate in the chronic obstructive pulmonary disease population: a systematic review and meta-analysis. Adv Respir Med. 2022;90(2):125-33.
- Nouira S, Bouida W, Grissa MH. Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomized trial. Am J Ther. 2014;21(3):152-8.
- Ni H, Aye SZ, Naing C. Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Syst Rev. 2022;5(5):CD013506.
- Shivanthan MC, Rajapakse S. Magnesium for acute exacerbation of chronic obstructive pulmonary disease: a systematic review of randomised trials. Annals of thoracic medicine. 2014;9(2):77.
- Comert S. Role of magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. J Resp Res. 2015;1(1):10-2.
- Bajracharya M, Acharya RP, Neupane RP, Sthapit R, Tamrakar AR. Nebulized Magnesium Sulphate Versus Saline as an Adjuvant in Acute Exacerbation of Chronic Obstructive Pulmonary Disease in a Tertiary Centre of Nepal: A Randomized Control Study. J Inst Med Nepal. 2021;43(1):5-10.
- Bhatti HU, Mushtaq Z, Arshad A, Khanum N, Joher I, Masood A. Nebulized Magnesium Sulphate vs Normal Saline as an Adjunct in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Pak J Med Health Sci. 2021;15(12):3694-6.
- Edwards L, Shirtcliffe P, Wadsworth K. Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax. 2013; 68(4): 338-43.
Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.